soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Type 2 Diabetes patients at high risk receiving demonstrated early and sustained improvements in glycated hemoglobin, body weight, systolic blood pressure, and lipid profiles vs placebo Oral Semaglutide and Cardiovascular Outcomes
Pay in 4 interest-free payments of $5.36 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13




























